PURPOSE/ OBJECTIVES: To assess change in specific cognitive processes during treatment with chemotherapy only among children with acute lymphoblastic leukemia (ALL). . DESIGN: A prospective, repeated measures design. . SETTING: Pediatric oncology treatment centers at Banner-University Medical Center Tucson/Banner Children's-Diamond Medical Center (University of Arizona) and Texas Children's Cancer and Hematology centers (Baylor College of Medicine) in Houston. . SAMPLE: 71 children with ALL, with a mean age of 6.18 years at the time of diagnosis. . METHODS: Using mixed-effects latent growth curve modeling with time since diagnosis as a fixed effect, age-adjusted standardized measures of working memory, processing speed, executive function, and attention were obtained and repeated about one and two years later. A subsample was tested for academic achievement at the end of treatment. . MAIN RESEARCH VARIABLES: Verbal working memory, visual spatial memory, processing speed, academic achievement, age, and gender. . FINDINGS: A significant main effect was observed for age at diagnosis on decline in verbal working memory during treatment. Planned contrasts revealed greater decline among children who were diagnosed when aged younger than five years compared to those diagnosed when aged five years or older. Decline in verbal working memory and achievement in letter-word identification and calculation skills were associated, and decline in spatial memory was associated with calculation. A main effect of gender was observed on processing speed, with female patients showing greater decline than male patients. . CONCLUSIONS: Findings from this study may guide the timing of interventions that could improve school achievement among survivors. . IMPLICATIONS FOR NURSING: Children undergoing treatment for ALL may experience issues with verbal working memory and increased difficulty in school. Nurses are in a position to refer parents and children to school resources for additional academic support.
PURPOSE/ OBJECTIVES: To assess change in specific cognitive processes during treatment with chemotherapy only among children with acute lymphoblastic leukemia (ALL). . DESIGN: A prospective, repeated measures design. . SETTING: Pediatric oncology treatment centers at Banner-University Medical Center Tucson/Banner Children's-Diamond Medical Center (University of Arizona) and Texas Children's Cancer and Hematology centers (Baylor College of Medicine) in Houston. . SAMPLE: 71 children with ALL, with a mean age of 6.18 years at the time of diagnosis. . METHODS: Using mixed-effects latent growth curve modeling with time since diagnosis as a fixed effect, age-adjusted standardized measures of working memory, processing speed, executive function, and attention were obtained and repeated about one and two years later. A subsample was tested for academic achievement at the end of treatment. . MAIN RESEARCH VARIABLES: Verbal working memory, visual spatial memory, processing speed, academic achievement, age, and gender. . FINDINGS: A significant main effect was observed for age at diagnosis on decline in verbal working memory during treatment. Planned contrasts revealed greater decline among children who were diagnosed when aged younger than five years compared to those diagnosed when aged five years or older. Decline in verbal working memory and achievement in letter-word identification and calculation skills were associated, and decline in spatial memory was associated with calculation. A main effect of gender was observed on processing speed, with female patients showing greater decline than male patients. . CONCLUSIONS: Findings from this study may guide the timing of interventions that could improve school achievement among survivors. . IMPLICATIONS FOR NURSING: Children undergoing treatment for ALL may experience issues with verbal working memory and increased difficulty in school. Nurses are in a position to refer parents and children to school resources for additional academic support.
Authors: Michelle N Edelmann; Kevin R Krull; Wei Liu; John O Glass; Qing Ji; Robert J Ogg; Noah D Sabin; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Wilburn E Reddick Journal: Brain Date: 2014-08-13 Impact factor: 13.501
Authors: Annemieke I Buizer; Leo M J de Sonneville; Marry M van den Heuvel-Eibrink; Anjo J P Veerman Journal: Pediatr Blood Cancer Date: 2005-09 Impact factor: 3.167
Authors: Maarten Mennes; Peter Stiers; Erik Vandenbussche; Gertrui Vercruysse; Anne Uyttebroeck; Geert De Meyer; Stefaan W Van Cool Journal: Pediatr Blood Cancer Date: 2005-05 Impact factor: 3.167
Authors: Micaela E Christopher; Akira Miyake; Janice M Keenan; Bruce Pennington; John C DeFries; Sally J Wadsworth; Erik Willcutt; Richard K Olson Journal: J Exp Psychol Gen Date: 2012-02-20
Authors: Peter D Slade; Brenda D Townes; Gail Rosenbaum; Isabel P Martins; Henrique Luis; Mario Bernardo; Michael D Martin; Timothy A Derouen Journal: Psychol Assess Date: 2008-12
Authors: L Wengenroth; C S Rueegg; G Michel; M E Gianinazzi; S Essig; N X von der Weid; M Grotzer; Claudia E Kuehni Journal: Pediatr Blood Cancer Date: 2015-02-02 Impact factor: 3.167
Authors: Jan Pieter Konsman; Collin J Laaker; Kelsey R Lloyd; Adam Hiltz; Brittany L Smith; Marissa A Smail; Teresa M Reyes Journal: Brain Behav Immun Date: 2021-10-14 Impact factor: 7.217